Berkshire Hathaway has held a stake in DaVita Inc. since the fourth quarter of 2011, when it first disclosed 5.3 million shares worth $203 million. The position grew to 12 million shares worth $541 million by the following quarter and reached 38.6 million shares by the end of 2014, a level maintained until late 2019. As of the first quarter of 2026, Berkshire held 30 million shares valued at $4.6 billion. Deutsche Bank upgraded DaVita to Buy from Hold on May 6th and raised its price target to $220 from $216, following first-quarter results that included revenue per treatment of $417.59 and operating income of $482 million.
DaVita HealthCare Partners IncDeutsche Bank upgraded DaVita to Buy and raised price target after strong Q1 results.
Berkshire Hathaway Inc
Deutsche Bank Aktiengesellschaft